CARTemis

CARTemis Therapeutics develops next-generation, personalized CAR T-cell therapies designed to eliminate hard-to-treat cancers by minimizing relapse risk and disrupting the tumor microenvironment and its surrounding defense network. A safe hybrid in vivo manufacturing approach aims to make this curative therapy broadly accessible and scalable.